What is the recommended CJC-1295 (No DAC) dosage?

CJC-1295 (No DAC) dosing varies by experience level. Beginners typically start at 100mcg daily, moderate users at 100mcg 2x daily, and aggressive protocols use 200mcg 2x daily.

How do you reconstitute CJC-1295 (No DAC)?

CJC-1295 (No DAC) typically comes in 2mg or 5mg vials. Add 2mL of bacteriostatic water to the vial. Use our free calculator for exact syringe units based on your desired dose.

What is the half-life of CJC-1295 (No DAC)?

The half-life of CJC-1295 (No DAC) is ~30 min. This determines how frequently you need to dose for consistent blood levels.

CJC-1295 (No DAC)

Growth HormoneInjectionResearchGrade B~30 min half-life

Growth Hormone SecretagogueGHRH AnalogPulsatile GH ReleaseAnti-AgingRecovery12 weeks on / 4 weeks off

Benefits

Natural pulsatile GH release

Synergistic when combined with Ipamorelin

No cortisol or prolactin elevation

Improves sleep and recovery

Promotes lean body composition

Half-Life

~30 min

Route

Injection

Frequency

Daily

Vial Sizes

2mg, 5mg

BAC Water

2mL

Safety Grade

Grade B

Open CJC-1295 (No DAC) Dosage Calculator

Calculate exact syringe units for your vial and dose

About CJC-1295 (No DAC)

CJC-1295 without DAC (also called Mod GRF 1-29) is a short-acting GHRH analog that produces natural, pulsatile growth hormone release. Unlike the DAC version, it has a short half-life (~30 min), which means it stimulates a GH pulse that mimics the body's natural rhythm. It's most commonly stacked with Ipamorelin for synergistic GH release without cortisol or prolactin spikes.

Who Should Consider CJC-1295 (No DAC)

Adults over 30 experiencing age-related GH decline (somatopause)
Athletes and bodybuilders seeking improved recovery and body composition
Individuals looking to improve sleep quality and depth
Post-injury patients wanting faster tissue repair
Those who prefer natural pulsatile GH release over sustained elevation

How CJC-1295 (No DAC) Works

CJC-1295 (No DAC) binds to the GHRH receptor on pituitary somatotroph cells, amplifying the natural growth hormone pulse. Its short half-life (~30 min) means it triggers a sharp GH spike that closely mimics natural physiology, rather than sustaining elevated levels. When combined with a GHRP like Ipamorelin, it amplifies the GH pulse that Ipamorelin triggers.

What to Expect

Week 1-2

Improved sleep quality and more vivid dreams. Some users report mild water retention and occasional facial flushing after injection.

Weeks 3-4

Noticeable improvements in recovery time between workouts. Skin hydration and texture begin to improve. Increased morning energy.

Months 2-3

Body composition shifts become apparent — reduced abdominal fat and improved muscle tone. Joint and connective tissue comfort improves.

Months 3-4

Full anti-aging and recovery benefits are established. Sustained fat loss, better exercise capacity, and improved skin elasticity.

Month 5+

Benefits plateau at this stage. Cycle off for 4 weeks to maintain pituitary receptor sensitivity before restarting protocol.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	100mcg	Daily
Moderate	100mcg	2x Daily
Aggressive	200mcg	2x Daily

Note: Mod GRF 1-29. Best stacked with Ipamorelin. Produces natural GH pulse. Dose on empty stomach.

How to Inject CJC-1295 (No DAC)

Inject subcutaneously on an empty stomach (no food 1 hour before or 30 minutes after). Best timing is before bed or post-workout. Inject at the same time as Ipamorelin if stacking.

Cycling Protocol

On Period

12 weeks

Off Period

4 weeks

Cycle to prevent pituitary desensitization. Some users run 5 days on, 2 days off weekly.

Pharmacokinetics

Half-Life

30min

Bioavailability

SC: estimated 90-95% for short GHRH analogs

Tmax

5-15 minutes (peak GH pulse occurs 15-30 min post-injection)

Data Confidence

moderate

Source: CJC-1295 without DAC (Mod GRF 1-29) t½ ~30 min; rapid clearance drives need for multiple daily injections (Teichman et al. 2006 PMID 16352683)

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Facial flushing, headache, dizziness (usually brief). Injection site irritation. Best taken on empty stomach.

Contraindications

Active cancer or history of malignancy — GH promotes cell proliferation
Diabetes mellitus — GH antagonizes insulin and may worsen blood sugar control
Pregnancy or breastfeeding
Active pituitary tumors or intracranial neoplasms
Known hypersensitivity to GHRH analogs
Untreated hypothyroidism — may blunt GH response

Drug Interactions

Insulin and oral hypoglycemics — GH release antagonizes insulin action; monitor blood glucose closely
Corticosteroids — chronic use may blunt GH response and reduce efficacy
Other GH secretagogues (GHRP-2, GHRP-6, Ipamorelin) — additive GH release increases side effect risk; use caution when stacking
Thyroid hormones — GH can accelerate T4-to-T3 conversion; monitor thyroid function
CYP3A4-metabolized drugs — GH may alter hepatic clearance rates